Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Trial Profile

A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Posterior uveitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors EyePoint Pharmaceuticals
  • Most Recent Events

    • 03 Oct 2019 According to an Alimera Sciences media release, INFARMED (the governmental agency that oversees the availability of medical products in Portugal) has granted marketing authorization on 1st Oct 2019 for ILUVIEN for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIPU).
    • 30 Jul 2019 According to an EyePoint Pharmaceuticals media release, results from the study were presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS).
    • 30 Jul 2019 Results presented in an EyePoint Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top